LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 159 filers reported holding LIGAND PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is 0.27 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $50,598,000 | +4.6% | 497,965 | +5.0% | 0.01% | -12.5% |
Q3 2016 | $48,390,000 | -18.7% | 474,130 | -5.0% | 0.01% | -20.0% |
Q2 2016 | $59,553,000 | +17.4% | 499,312 | +5.4% | 0.01% | +25.0% |
Q1 2016 | $50,712,000 | -1.2% | 473,544 | +0.0% | 0.01% | 0.0% |
Q4 2015 | $51,330,000 | +26.3% | 473,441 | -0.3% | 0.01% | +14.3% |
Q3 2015 | $40,657,000 | -22.1% | 474,691 | -8.2% | 0.01% | -12.5% |
Q2 2015 | $52,200,000 | +18.5% | 517,342 | -9.4% | 0.01% | +14.3% |
Q1 2015 | $44,037,000 | +42.5% | 571,094 | -1.6% | 0.01% | +40.0% |
Q4 2014 | $30,897,000 | +20.2% | 580,662 | +6.2% | 0.01% | +25.0% |
Q3 2014 | $25,696,000 | -30.4% | 546,847 | -7.8% | 0.00% | -33.3% |
Q2 2014 | $36,944,000 | -3.9% | 593,089 | +3.8% | 0.01% | -14.3% |
Q1 2014 | $38,430,000 | +33.3% | 571,286 | +4.2% | 0.01% | +40.0% |
Q4 2013 | $28,831,000 | +16.4% | 548,110 | -4.2% | 0.01% | 0.0% |
Q3 2013 | $24,771,000 | -1.4% | 572,344 | -14.8% | 0.01% | 0.0% |
Q2 2013 | $25,128,000 | – | 671,874 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 2,626,160 | $138,136,000 | 24.17% |
KNOTT DAVID M | 1,292,566 | $67,988,972,000 | 13.87% |
GROW Partners, LLC | 200,000 | $10,520,000 | 6.41% |
Opaleye Management Inc. | 90,000 | $4,860,000,000 | 3.82% |
OBERWEIS ASSET MANAGEMENT INC/ | 213,317 | $11,220,000 | 2.72% |
First Light Asset Management, LLC | 60,242 | $3,169,000 | 2.69% |
Timpani Capital Management LLC | 98,956 | $5,205,000 | 2.59% |
Iguana Healthcare Management, LLC | 75,000 | $3,945,000 | 2.25% |
Eventide Asset Management | 134,400 | $7,069,000 | 2.18% |
ASHFORD CAPITAL MANAGEMENT INC | 215,223 | $11,321,000 | 2.16% |